StockData
Olema Oncology, Inc. logo

Olema Oncology, Inc. (OLMA) stock

OLMANasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 10, 2026Score 8/30
$7.36−0.20 (-2.65%)

Close on Nov 16, 2026Market cap $643.98MP/E –Yield –

Olema Oncology r&d expenses

Research and development expenses are spending on new products and technology.

Olema Oncology's R&D Expenses for the twelve months ending Jun 30, 2026 was $190.19M, up 35.8% year over year. For fiscal 2025 it was $157.70M, up 26.6% from the year before. The highest annual figure on record is $157.70M in fiscal 2025.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$157.70M+26.6%
FY2024Dec 31, 2024$124.52M+44.6%
FY2023Dec 31, 2023$86.14M+4.7%
FY2022Dec 31, 2022$82.27M+61.0%
FY2021Dec 31, 2021$51.10M+272.9%
FY2020Dec 31, 2020$13.70M+249.6%
FY2019Dec 31, 2019$3.92M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$57.79M+31.6%
Q1 FY2026Mar 31, 2026$49.23M+60.8%
Q4 FY2025Dec 31, 2025$43.22M+33.8%
Q3 FY2025Sep 30, 2025$39.95M+20.2%
Q2 FY2025Jun 30, 2025$43.90M+50.8%
Q1 FY2025Mar 31, 2025$30.62M+2.5%
Q4 FY2024Dec 31, 2024$32.30M+24.8%
Q3 FY2024Sep 30, 2024$33.23M+70.8%
Q2 FY2024Jun 30, 2024$29.11M+61.8%
Q1 FY2024Mar 31, 2024$29.88M+30.9%
Q4 FY2023Dec 31, 2023$25.87M+19.9%
Q3 FY2023Sep 30, 2023$19.45M+10.4%
Q2 FY2023Jun 30, 2023$17.99M-33.5%
Q1 FY2023Mar 31, 2023$22.83M+42.6%
Q4 FY2022Dec 31, 2022$21.58M+35.1%
Q3 FY2022Sep 30, 2022$17.63M+40.8%
Q2 FY2022Jun 30, 2022$27.05M+127.2%
Q1 FY2022Mar 31, 2022$16.01M+49.7%
Q4 FY2021Dec 31, 2021$15.98M+154.0%
Q3 FY2021Sep 30, 2021$12.52M+168.0%
Q2 FY2021Jun 30, 2021$11.91M+511.7%
Q1 FY2021Mar 31, 2021$10.69M+1244.9%
Q4 FY2020Dec 31, 2020$6.29M–
Q3 FY2020Sep 30, 2020$4.67M–
Q2 FY2020Jun 30, 2020$1.95M–
Q1 FY2020Mar 31, 2020$795.00K–

More Olema Oncology figures

See a number that looks wrong?